Aptevo Therapeutics (APVO) Total Liabilities (2015 - 2026)
Aptevo Therapeutics (APVO) posted Total Liabilities of $8.3 million for Q1 2026, down 15.52% sequentially from $9.8 million in Q4 2025, and down 15.54% YoY from $9.8 million in Q1 2025.
Aptevo Therapeutics (APVO) Total Liabilities (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Total Liabilities for 12 years, with the latest figure at $8.3 million in Q1 2026.
- Quarterly Total Liabilities fell 15.54% year-over-year to $8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.3 million (down 15.54% YoY) and the FY2025 annual result came in at $9.8 million, down 9.44% from the prior year.
- Total Liabilities retreated to $8.3 million in Q1 2026 per APVO's latest filing, from $9.8 million in the prior quarter.
- Over five years, Total Liabilities peaked at $51.1 million in Q1 2022 and troughed at $8.3 million in Q1 2026.
- A 5-year average of $14.0 million and a median of $11.5 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities slumped 77.06% in 2023, then slipped 1.6% in 2024.
- Over 5 years, Total Liabilities stood at $16.2 million in 2022, then dropped by 22.29% to $12.6 million in 2023, then declined by 14.14% to $10.8 million in 2024, then slipped by 9.44% to $9.8 million in 2025, then decreased by 15.52% to $8.3 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $8.3 million, $9.8 million, and $9.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 10.03 Bn |
| 10 | Aptevo Therapeutics | 3.40 Mn | -6.40 Mn | - | 8.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.48 Mn |
| Mar 31, 2026 | 8.29 Mn |
| Dec 31, 2025 | 9.81 Mn |
| Sep 30, 2025 | 9.60 Mn |
| Jun 30, 2025 | 9.10 Mn |
| Mar 31, 2025 | 9.82 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | 10.73 Mn |
| Jun 30, 2024 | 10.46 Mn |
| Mar 31, 2024 | 11.53 Mn |
| Dec 31, 2023 | 12.62 Mn |
| Sep 30, 2023 | 12.41 Mn |
| Jun 30, 2023 | 12.66 Mn |
| Mar 31, 2023 | 11.71 Mn |
| Dec 31, 2022 | 16.24 Mn |
| Sep 30, 2022 | 15.93 Mn |
| Jun 30, 2022 | 15.75 Mn |
| Mar 31, 2022 | 51.07 Mn |
| Dec 31, 2021 | 55.39 Mn |
| Sep 30, 2021 | 56.71 Mn |